IQ Announces key Milestone in Development of Anthrax Monoclonal Antibody Treatments
Complete the form below to unlock access to ALL audio articles.
IQ Corporation has announced the completion of PER.C6® clone generation for the production of its two fully human monoclonal antibodies against the anthrax lethal toxin components Lethal Factor and Protective Antigen.
The clone generation programs were conducted by Invitrogen's PD-Direct™ services for IQ under a licensing agreement with Crucell N.V. and DSM.
"We are very excited about the successful achievement of our clone generation objectives," said Dr. Herman Groen, Chief Scientific Officer at IQ.
"It enables IQ to advance its unique strategy of the combined application of two different monoclonal antibodies for the treatment of anthrax."
"Invitrogen's expertise in cell line development and knowledge of the PER.C6® platform was a tremendous asset in the timely completion of this important milestone."
"We are very pleased to have the opportunity to contribute to IQ's product development," noted Chris Linthwaite, General Manager for Invitrogen PD-Direct services.
"The PER.C6 clone generation program is a good example of the value that Invitrogen can bring to clients through our PD-Direct services."
